EICHORCondition: Overweight · Obesity · Sponsor: Novo Nordisk A/S
Interested? Contact the study team ↓
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
This description comes directly from the study's public registry record.
Novo Nordisk · (+1) 866-867-7178 · clinicaltrials@novonordisk.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Initiation of semaglutide for weight management during the study period. * Age more than or equal to (≥) 18 at treatment initiation * Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2. * Other inclusion criteria as defined in the protocol are applicable. Exclusion Criteria: * Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs). * Bariatric surgery at baseline. * Diabetes at baseline. * Pregnancy at baseline.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Novo Nordisk Investigational Site | Seattle, Washington, United States | Recruiting |
| Novo Nordisk Investigational Site | London, United Kingdom | Recruiting |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07627074